# US 2025/0207183 A1 · Spatially encoded biological assays

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0207183 A1
- Document ID: US20250207183A1
- Status: Published application
- Kind: A1
- Application number: 19/074,001
- Filed: 2025-03-07
- Published: 2025-06-26
- Earliest claimed: 2010-04-05
- Assignees: Prognosys Biosciences, Inc.
- Applicants: Prognosys Biosciences, Inc.
- Inventors: Mark S. Chee
- Web page: https://patentgrep.com/patent/US20250207183A1

## CPC

- C12Q 1/6837: using probe arrays or probe chips (C12Q1/6874 takes precedence)
- B01L 3/502715: {characterised by interfacing components, e.g. fluidic, electrical, optical or mechanical interfaces}
- C12Q 1/68: involving nucleic acids
- C12Q 1/6804: Nucleic acid analysis using immunogens (immunoassay G01N33/53)
- C12Q 1/6809: Methods for determination or identification of nucleic acids involving differential detection
- C12Q 1/6834: Enzymatic or biochemical coupling of nucleic acids to a solid phase
- C12Q 1/6841: In situ hybridisation
- C12Q 1/6869: Methods for sequencing
- C12Q 1/6874: involving nucleic acid arrays, e.g. sequencing by hybridisation
- C12Q 1/6876: Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C40B 30/04: by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
- C40B 60/04: Integrated apparatus specially adapted for both screening libraries and identifying library members
- G01N 33/5308: {for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites}
- G01N 33/543: with an insoluble carrier for immobilising immunochemicals
- G01N 33/54366: {Apparatus specially adapted for solid-phase testing}
- G01N 33/6845: {Methods of identifying protein-protein interactions in protein mixtures}
- G01N 33/6848: {Methods of protein analysis involving mass spectrometry}
- C12Q 1/6858: Allele-specific amplification
- C12Q 2600/156: Polymorphic or mutational markers
- C12Q 2600/158: Expression markers
- G01N 2458/10: Oligonucleotides as tagging agents for labelling antibodies
- G01N 2458/40: Rare earth chelates
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- B01L: CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- C40B: COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES (in silico combinatorial libraries of nucleic acids, proteins or peptides G16B35/00; in silico combinatorial chemistry G16C20/60)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention provides assays and assay systems for use in spatially encoded biological assays. The invention provides an assay system comprising an assay capable of high levels of multiplexing where reagents are provided to a biological sample in defined spatial patterns; instrumentation capable of controlled delivery of reagents according to the spatial patterns; and a decoding scheme providing a readout that is digital in nature.

## Claims

### Claim at position 1

1-20. (canceled)

### Claim 21

A method comprising:
(a) providing a substrate comprising a plurality of nucleic acid molecules each having (i) a first sequence configured to bind a target biological molecule in a tissue section, and (ii) a second sequence corresponding to a location on the substrate;
(b) contacting the tissue section with the substrate;
(c) capturing the target biological molecule from the tissue section onto a nucleic acid molecule of the plurality of nucleic acid molecules using the first sequence; and
(d) generating a nucleic acid molecule comprising (i) a sequence of the captured target biological molecule, or a complement thereof, and (ii) the second sequence corresponding to the location on the substrate, or a complement thereof.

### Claim 22 (depends on 21)

The method of claim 21, wherein the tissue section is a fresh-frozen or formalin-fixed paraffin-embedded tissue sample.

### Claim 23 (depends on 21)

The method of claim 21, wherein the target biological molecule is an RNA molecule.

### Claim 24 (depends on 23)

The method of claim 23, wherein the RNA molecule is an mRNA molecule.

### Claim 25 (depends on 21)

The method of claim 21, wherein the target biological molecule is a DNA molecule.

### Claim 26 (depends on 21)

The method of claim 21, wherein (c) comprises hybridizing the target biological molecule to the first sequence of the nucleic acid molecule.

### Claim 27 (depends on 21)

The method of claim 21, wherein (c) comprises coupling the target biological molecule to the nucleic acid molecule.

### Claim 28 (depends on 27)

The method of claim 27, wherein the coupling comprises ligation.

### Claim 29 (depends on 28)

The method of claim 28, wherein the ligation comprises enzymatic ligation.

### Claim 30 (depends on 21)

The method of claim 21, wherein (d) comprises extending the nucleic acid molecule using the target biological molecule as a template.

### Claim 31 (depends on 30)

The method of claim 30, wherein the extending is performed by a polymerase.

### Claim 32 (depends on 21)

The method of claim 21, wherein the substrate is a flow cell.

### Claim 33 (depends on 21)

The method of claim 21, wherein the plurality of nucleic acid molecules further comprises a universal priming site.

### Claim 34 (depends on 21)

The method of claim 21, further comprising staining the tissue section.

### Claim 35 (depends on 34)

The method of claim 34, wherein the staining is selected from immunohistochemistry or hematoxylin and eosin staining.

### Claim 36 (depends on 34)

The method of claim 34, further comprising obtaining an image of the stained tissue section.

### Claim 37 (depends on 21)

The method of claim 21, further comprising amplifying the generated nucleic acid molecule.

### Claim 38 (depends on 37)

The method of claim 37, further comprising sequencing all or a portion of the amplified, generated nucleic acid molecule.

### Claim 39 (depends on 21)

The method of claim 21, further comprising determining the location on the substrate where the target biological molecule was captured.

### Claim 40 (depends on 39)

The method of claim 39, wherein the method further comprises mapping the location of the target biological molecule to a location in the tissue section.
